The 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics 2017 is dedicated to current challenges, best practices and the inside view of the future of ADCs.
The 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics 2017 covers topics such as:
- Emerging discoveries, cutting-edge knowledge, tools, methods, and technologies to design safe and efficient next-generation ADCs
- 360° view of Antibody Drug Conjugates (ADCs) from key industry players to leverage your business and scientific practice adoption
- Approaches to improve the ADC therapeutic risk-benefit ratio, to create new paradigm for novel anti-cancer chemotherapy, to expand the application of ADCs beyond oncology and haematology
- Strategies to improve target selection, increase cytotoxic potency, explore developments of novel linker chemistry, applied to next-generation payloads, discover emerging conjugation methods, accelerate preclinical development, and successfully translate into the clinic
The 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics 2017 brings together attendees involved or interested in:
- Manufacturing/CMC
- Antibody & Biologics Discovery /Development
- Molecular Biology
- Protein Engineering
- Antibody-drug conjugates (ADCs)
- Medicinal Chemistry
- Immunoconjugates
- Bioconjugates
- Maytansine
- Monoclonal antibodies (mAbs)
- Duocarmycin
- Tubulysins
- α-amanitin
- PBD-dimers
- Marine-based cytotoxins
- Topoisomerase inhibitors
- Peptide-drug conjugates
- Small-molecule drug conjugates
- Diabodies/Minibodies
- Nanoparticles/Nanobodies
- ADME
- PKPD
- Analytical & Formulation
- Toxicology
- Cancer
- Bioanalysis
- Hematology
- Oncology
- Biotherapeutics
- Antibody-based therapeutics
- Chemotherapeutics
- Immunotherapeutics
